Pfizer inc (PFE)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Revenues

51,750

53,647

52,546

52,824

48,851

49,605

51,584

54,657

61,035

65,165

49,269

48,296

48,418

Costs and expenses:
Cost of sales

10,219

11,248

11,228

12,322

9,648

9,577

9,586

9,821

12,500

14,788

8,459

8,112

11,239

Selling, informational and administrative expenses

14,350

14,455

14,804

14,844

14,809

14,097

14,355

15,171

17,581

18,973

14,752

14,537

15,626

Research and development expenses

8,650

8,006

7,683

7,892

7,690

8,393

6,678

7,482

8,681

9,483

7,824

7,945

8,089

Amortization of intangible assets

4,610

4,893

4,758

4,056

3,728

4,039

4,599

5,109

5,465

5,364

2,877

2,668

3,128

Acquisition-related in-process research and development charges

-

-

-

-

-

-

-

-

-

-

68

633

283

Restructuring charges and certain acquisition-related costs

747

1,044

351

1,565

1,152

250

1,182

1,810

2,841

3,145

4,330

2,675

2,534

(Gain) on completion of Consumer Healthcare JV transaction

8,086

0

0

-

-

-

-

-

-

-

-

-

-

Other Nonoperating Income (Expense)

-3,578

-2,116

-1,416

-3,794

-2,860

-1,009

532

-4,022

-2,486

-3,941

-285

2,032

-1,759

Income from continuing operations before provision for taxes on income

17,682

11,885

12,305

8,351

8,965

12,240

15,716

11,242

11,481

9,471

10,674

9,694

9,278

Provision for taxes on income

1,384

706

-9,049

1,123

1,990

3,120

4,306

2,221

3,621

1,153

2,145

1,645

1,023

Income from continuing operations

16,298

11,179

21,353

7,229

6,975

9,119

11,410

9,021

7,860

8,318

8,529

8,049

8,255

Discontinued operations:
Income from discontinued operations––net of tax

4

10

-1

16

17

-6

308

794

885

-19

97

-

-

Gain on disposal of discontinued operations––net of tax

0

0

3

0

-6

55

10,354

4,783

1,304

-11

17

-

-

Discontinued operations––net of tax

4

10

2

17

11

48

10,662

5,577

2,189

-30

114

78

-69

Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

16,302

11,188

21,355

7,246

6,986

9,168

22,072

14,598

10,049

8,288

8,643

8,127

8,186

Less: Net income attributable to noncontrolling interests

29

36

47

31

26

32

69

28

40

31

8

23

42

Net income attributable to Pfizer Inc.

16,273

11,153

21,308

7,215

6,960

9,135

22,003

14,570

10,009

8,257

8,635

8,104

8,144

Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)

2.92

1.90

3.57

1.18

1.13

1.43

1.67

1.21

1.00

1.03

1.22

1.19

1.19

Discontinued operations––net of tax (in dollars per share)

0.00

0.00

0.00

0.00

0.00

0.01

1.56

0.75

0.28

0.00

0.02

0.01

-0.01

Net income attributable to Pfizer Inc. common shareholders (in dollars per share)

2.92

1.90

3.57

1.18

1.13

1.44

3.23

1.96

1.28

1.03

1.23

1.20

1.18

Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)

2.87

1.86

3.52

1.17

1.11

1.41

1.65

1.20

0.99

1.03

1.21

1.19

1.18

Discontinued operations––net of tax (in dollars per share)

0.00

0.00

0.00

0.00

0.00

0.01

1.54

0.74

0.28

0.00

0.02

0.01

-0.01

Net income attributable to Pfizer Inc. common shareholders (in dollars per share)

2.87

1.87

3.52

1.17

1.11

1.42

3.19

1.94

1.27

1.02

1.23

1.20

1.17

Weighted-average shares––basic

5,569

5,872

5,970

6,089

6,176

6,346

6,813

7,442

7,817

8,036

7,007

6,727

6,917

Weighted-average shares––diluted

5,675

5,977

6,058

6,159

6,257

6,424

6,895

7,508

7,870

8,074

7,045

6,750

6,939

Cash dividends paid per common share (in dollars per share)

-

-

-

-

1.12

1.04

0.96

0.88

0.80

0.72

-

-

-